Catalyst Wire Dossier Catalyst Wire Dossier

PF-04523655

· Quark Pharmaceuticals
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for PF-04523655, covering 2012-10-11 to 2015-02-23. Get the full timeline:

Most recent: Clinical Trial Update: PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) [Phase 2]

See pricing